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MANAGEMENT OF PRIMARY VENOUS
DISORDERS IN C6 PATIENTS
—Michel. R. Perrin, MD, Lyon, France
The highest clinical class of venous disorders in the
CEAP classification is C6. To decrease venous ulcer preva-
lence, two steps are necessary: first, healing the ulcer, and
second, preventing its recurrence. It must be kept in mind
that primary etiology is not only identified in the superficial
venous system, but encompasses the perforator and deep
systems, which means that all of the venous system must be
investigated in patients presenting with an ulcer - at least by
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of the different reflux locations have been evaluated in
numerous surveys, but in most of them the etiology is not
specified.1-8 Only two studies give both information on
etiology and reflux location.9,10 More recently, it has been
pointed out that ilio-caval primary obstruction is an under-
estimated cause of severe chronic venous insufficiency.11,12
This information on etiology and pathophysiologic disor-
ders is not only of academic interest but is crucial if opera-
tive treatment is considered. Conversely, when conservative
treatment is used, the above mentioned information is not
important as treatment relies mostly on symptoms and
signs.
The purpose of this study was to get precise and com-
plete information, which investigations are compulsory in
patients with C5 to C6 disease. Level 2 investigations, as
described in the CEAP classification, must be carried out in
all patients.13 Additional investigations have to be under-
taken according to various situations when operative treat-
ment is considered. In patients with C5 to C6 disease with
moderate superficial reflux and absence of primary deep
reflux, primary obstruction is possible. Venography, ac-
cording to Raju and Neglén,11 underestimates iliocaval
vein compression and intravascular ultrasound scan should
be undertaken to identify this anomaly.12,14 The problem is
that iliocaval vein compression and intravascular ultrasound
scan is invasive and expensive. In patients with axial deep
reflux and when valve reconstruction is considered, de-
scending venography is the best investigation to determine
the optimal technique to be used.15
TREATMENT
Ulcer healing. Most of the studies devoted to venous
ulcer healing do not give detailed information on etiology
and pathophysiologic disorders. Whatever they are, com-
pression remains the first-line of treatment for healing
venous ulcers. In a retrospective review of 113 patients with
venous ulcers, complete ulcer healing occurred in 99 of 102
patients (97%) who complied with the use of stockings vs 6
of 11 patients (55%) who were not compliant (P 
.0001).16 Another retrospective review of 99 venous ulcers
confirmed this data17 and Cochrane review.18
There is a strong recommendation (grade 1B) for using
compression for healing ulcers, whatever the etiology and
the physiopathology.19
The question arises: does operative treatment enhance
healing? Three randomized controlled studies (RCTs)
comparing superficial venous surgery  compression vs
compression alone are available.
The ESCHAR study concluded that correction of su-
perficial venous reflux in addition to compression bandag-
ing did not improve the ulcer healing rate whether the
etiology was primary or secondary.20,21
In another RCT including 76 patients of primary and
secondary etiology presenting with superficial venous reflux
/ deep venous reflux / perforator incompetence
were randomized into two arms: compression alone and
varicose vein surgery  compression. Superficial venoussurgery gave no additional benefit to compression therapy
from the point of view of healing rate and quality of life.22
In the third RCT, 200 ulcerated legs (C6) were ran-
domized and treated by varicose vein surgery / perfo-
rator ligation  compression vs compression alone, know-
ing that primary and secondary patients with segmental and
axial deep reflux were included. Healing rate was not sta-
tistically different whatever the etiology, pathophysiologic
disorder, or treatment.23
Conversely, in an Italian series of isolated primary re-
flux, 80 patients (87 extremities) were treated by minimally
invasive surgery (CHIVA technique) vs compression. The
healing rate was better in the surgical group P  .02, but
ulcers 12 cm were excluded; there is no information on
postoperative compression in the surgical group and in
both groups the healing time was abnormally short.24
Many observational studies support various operative
treatments in primary varices to improve ulcer healing, but
none of them includes a control group. In conclusion, there
is no recommendation for using operative treatment to
improve ulcer healing rate.
The effectiveness of a venoactive drug in improving
ulcer healing has been assessed in a meta-analysis including
five large European studies (n 723). Its administration to
patients had a statistically significant effect on the healing of
medium size trophic ulcers (5-10 cm2) that had persisted
for 6 to 12months. In addition, healing time was shortened
by 5 weeks. The authors concluded that venoactive drugs
might be an appropriate and valuable addition to standard
therapy of venous leg ulcers.25 In the Handbook of Venous
Disorders, two venoactive drugs in combination with com-
pression are given a grade 1B recommendation whatever
the etiology in long-standing or large venous ulcers.26
Several observational studies pointed out that the heal-
ing rate is improved when patients are managed by special-
ized centers on an ambulatory basis.27-29
The types of compression (stocking and bandages) will
not be broached in this review nor will local treatment.
Ulcer recurrence prevention. Usually, effectiveness
and value of operative treatments are compared with con-
servative treatments, in other words, compression. The
problem is that compliance with compression is very diffi-
cult to assess in a long-term follow-up. According to a
survey including a large cohort of patients under the care of
primary care physicians and specialists, 63% of patients did
not use the stockings prescribed and there was no differ-
ence between the C0s to C2 and the C3 to C6 group.30
Long-term compliance in the Milwaukee’s group was also
poor, 67.7% vs 32.3%.17
It is regrettable that most articles on compression treat-
ment outcome do not make a difference between primary
and secondary etiology and the venous system involved or
the pathophysiologic disorder anomaly responsible for the
venous ulcer. Conversely, operative treatment must take
into account the venous systems involved and the patho-
physiologic anomaly, which is to say to the A and P CEAP
headings.
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varices), the three RCTs already quoted are reliable. In the
ESCHAR study, rates of ulcer recurrence at 4 years were
56% for the compression group (group 1) and 31% for the
compression  surgery group (group 2; P  .01). What is
particularly interesting in this prospective study is the fact
that isolated superficial reflux, or combined with deep
reflux, was evaluated separately.21
For patients with isolated superficial reflux, recurrence
rates were respectively 27% in group 2 vs 51% in group 1, P
 .01. For patients who had superficial with segmental
deep reflux, recurrence rates at 3 years were 52% for group
1 and 24% for group 2, P  .04. In the last subgroup,
combining deep axial reflux as defined in the vein-term
consensus,31 recurrence rates at 3 years were 46% for group
1 and 32% for group 2, P  .33.
In the Dutch RCT already mentioned, the conclusion
was that only patients with medial and/or recurrent ulcer
had better results with superficial surgery / superficial
endoscopic perforator vein surgery whatever the etiology
and the presence or absence of deep reflux, but this infor-
mation is not clear because the CEAP classification was not
used in describing the patients.
In the Italian series, the recurrence rate was 9% in the
surgical group vs 36% in the compression group at 3-year
follow-up, P  .05.24
There is no RCT available both for thermal ablation or
chemical ablation, but their outcome in patients without
healed or active ulcer is as good as conventional surgery.
In conclusion, in patients with isolated primary varices,
treatment by open surgery to prevent venous ulcer recur-
rence is a strong recommendation (1A); as far as other
operative treatments (thermal and chemical ablation) are
concerned, data have not been reported.
Table. Valvuloplasty results
Author year
Surgical
technique
Number of limbs
(number of
valves repaired)
Etiology
PVI/total
Fo
Masuda 1994 I 32 27/32 48
Lehtola 2008 I 12 5/12 24
TMEV 7 3/7
ITMEV 1 0/1
Perrin 2000 I 85 (94) 65/85 12
Raju 1996 I 68 (71) – 12
Raju 1996 TMEV 47 (111) – 12
Raju 2000 TCEV 141(179) 98/141 1-4
Rosales 2006 TMEV 17 (40) 17/17 3-1
Sottiurai 1988 I 143 – 9-1
Tripathi 2004 I 90 (144) 118 (24
TMEV 12 (19)
Wang 2006 TMEV (40) 40/40 (36
I, Internal valvuloplasty; PVI, primary venous insufficiency; TMEV, transmur
ambulatory venous pressure;  VRT, venous refill time; av, average;m, improvedAt the present time, there is no RCT comparing out-
come in patients treated by surgery and wearing or not
wearing long-term postoperative compression stockings.
In patients combining superficial and deep reflux, the
boundary is the extension of the reflux; when it is segmen-
tal, operative treatment of superficial reflux remains a
strong recommendation (1C). Nevertheless, to determine
if patients would be really improved by operative treatment
of their superficial reflux, Marston et al32 has suggested
taking into account the preoperative value of maximum
reflux velocity measured in the femoral and popliteal vein.
If the velocity is more than 10 cm/second, the effectiveness
of operative treatment is doubtful.
When axial deep reflux is also present, it is known that
about 50% of patients will not be improved by superficial
venous surgery.33 Their optimal management will be dis-
cussed later and in the combination of primary obstruction
with superficial reflux.
Another unsolved question is related to perforator in-
sufficiency combined with superficial reflux. Again, there is
no RCT comparing the outcome of C5 to C6 disease in
patients treated operatively by isolated superficial venous
surgery vs suppression of incompetent perforators in com-
bination. Nevertheless, re-ulceration has been cured by
complementary perforator ablation in observational series.
Isolated primary perforator insufficiency is a rare con-
dition, but in the presence of venous ulceration, there is a
weak recommendation (grade 2B) for treating them oper-
atively as there is no RCT comparing operative treatment
including sclerotherapy34 with compression.
Deep venous reconstructive surgery remains the most
debated topic. Both its long-term effectiveness and superi-
ority, if compared with compression, are still controversial,
essentially because precise information on compression
p mos
n)
Ulcer recurrence
or nonhealed
ulcer (%) Results
Competent AVP□
valve (%) VRT 
(127) (28) 24/31 (77) □m 81% (av)
m 50% (av)
4) – (55) –
8) 10/35 (29) 72/94 (77)  Normalized
63% (av)
16/68 (26) 30/71 (42) –
14/47 (30) 72/111 –
(37) (59) □m 15% (av)
 Normalized
100%
0) 3/7 (43) (52) □m 50% (av)
1) 9/42 (21) 107/143 (75) –
(32) (79.8) –
(50) (31.5) –
– (91) m 50% (av)
rnal valvuloplasty; TCEV, transcommissural external valvuloplasty;□AVP,llow-u
(mea
-252
-78 (5
-96 (5
-144
-70
2
22 (6
68 (8
)
)
al exte
.
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obstruction C5 to C6 and in patients with primary deep
axial reflux.
Observational studies are available both for obstruction
and reflux. Furthermore, most patients with axial deep
reflux were failures of conservative treatment and/or super-
ficial and perforator operative treatment. Outcomes after
valvuloplasty are presented in the Table. It is worth noting
that, in all studies, there was a good correlation between
absence of ulcer recurrence, repaired valve competence,
and hemodynamic results. Valve reconstruction is recom-
mended in primary axial deep reflux after less invasive
therapies have failed or in young and active patients reluc-
tant to wear permanent compression (recommendation
1A).
In primary iliocaval obstruction, only one large series
has been reported.35 Among 982 chronic nonmalignant
obstructive lesions of the femoroiliocaval vein which were
stented, 517were of primary etiology. Seventeen percent of
the extremities treated had an open ulcer. Healing of leg
ulcers was followed-up in 148 of 158 limbs for a mean 23
months (range, 1-99 months). In 47 limbs (31.7%), the
ulcer did not heal. In the remaining 101 limbs, the ulcer
healed and recurred in only 8 limbs during the follow-up
period. Thus, if healing of the ulcer was achieved after this
intervention, ulcer recurrence was rare within the study
period. The cumulative rate of ulcer healing at 5 years was
58% overall: 62% for nonthrombotic iliac vein lesion, in
other words primary etiology, and 55% for thrombotic
limbs (P  .2819). In a few cases, superficial venous insuf-
ficiency was treated in combination. The authors con-
cluded that the beneficial clinical outcome occurred regard-
less of the presence of remaining reflux, adjunct saphenous
procedures, or etiology. However, almost one-third of the
patients did not heal. It is not known whether they had a
combination of superficial or deep reflux that was not
treated. This point might explain the high percentage of
non-healing ulcers.
In primary chronic iliac vein obstruction in patients
with C6 disease, stenting is recommended (recommenda-
tion 1A). Nevertheless, when extended reflux is also present
and if the ulcer does not heal after stenting, correction of
the reflux must be considered.
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SUMMARY OF EVIDENCE OF EFFECTIVENESS
OF PRIMARY CHRONIC VENOUS DISEASE
TREATMENT
—William Marston, MD, Chapel Hill, NC
COMPRESSION AFTER DEEP VENOUS
THROMBOSIS TO PREVENT POST-
THROMBOTIC SYNDROME AND
ULCERATION
ACochrane review of non-pharmaceutical measures for
prevention of postthrombotic syndrome identified three
randomized controlled trials (RCTs) evaluating compres-
sion stockings to no compression or sham compression in
patients after an episode of deep vein thrombosis (DVT).1
The use of compression stockings in each study was associ-
ated with a significant reduction of the development of
postthrombotic syndrome (PTS; odds ratio 0.39). Because
the incidence of venous ulceration after DVT is low
(10%) and may not present for more than 10 years after
the initial event, randomized studies on the prevention of
ulceration after DVT are unlikely to be performed.
The use of compression hosiery to prevent PTS after
DVT can be given a 1A recommendation based on the clear
benefit and low-risk of complications, but for prevention of
ulceration, a 1C grade is recommended as a prevention of
PTS is only a surrogate for ulcer prevention. It may also be
argued that a treatment modality that suffers from poor
patient compliance (fewer than 50% of DVT patients are
estimated to routinely wear compression stockings long-
term) should not be assigned a 1 grade because patients
frequently decide that the therapy is not worth the sup-
posed treatment benefit.COMPRESSION FOR VENOUS ULCER
HEALING AND PREVENTION OF
RECURRENCE
TheCochraneCollaboration recently (January 2009) up-
dated their extensive review of the literature on the use of
compression for venous leg ulcers.2 After a review of 39RCTs
examining various forms of compression in venous leg ulcers,
they concluded that compression clearly increases ulcer heal-
ing rates compared to no compression. Multi-component
systems are more effective than single-component systems,
and most studies found that multi-component systems with
an elastic bandage were more effective than those composed
mainly of inelastic components.
An RCT of 153 patients compared the effectiveness of
compression hosiery in reducing the incidence of ulcer recur-
rence after healing.3 Significantly fewer patients using com-
pression routinely developed ulcer recurrence at 6 months of
follow-up (21%) thandid those not using compressionhosiery
(46%; P  .05). Another RCT compared the relative benefit
of class 2 compression stockings compared to class 3 stockings
in preventing ulcer recurrence.4Whereas no significant differ-
ence in the incidence of ulcer recurrence was found (32%
recurred using class 3 and 39% recurred using class 2), 42% of
patients randomized to class 3 hosiery were unable to comply
with their use, potentially masking the ability to prevent
recurrence in this group. In the class 2 group, 28% of patients
were noncompliant with routine use.
Based on this analysis, it seems appropriate to assign a
1A grade to the use of compression bandaging for the
healing of venous leg ulcers. A grade of 1B seems reason-
able for the recommendation of compression hosiery to
prevent recurrent ulceration. There is little risk to compres-
sion bandaging and hosiery as long as patients with arterial
insufficiency are identified and appropriate stocking sizing
and training is performed. However, it must be acknowl-
edged that compliance with high-grade compression ho-
siery is poor, and in many cases lower amounts of compres-
sion may be preferable to achieve compliance.
MEDICAL THERAPIES FOR TREATMENT OF
PRIMARY CHRONIC VENOUS DISEASE AND
ACCELERATION OF ULCER HEALING:
PHLEBOTONIC AGENTS
The category of phlebotonic agents contains a variety of
natural and synthetic compounds believed to have “venoac-
tive properties” that will reduce the symptoms of venous
disease. These properties include a reduction of capillary per-
meability, improvement of venous tone, inhibition of inflam-
mation or leukocyte activation, and others. Flavonoids, natu-
ral extracts from plants such as grape seed and French
maritime pine bark, are included in this category, as are horse
chestnut seed extract (HCSE) and rutosides.
In a recent review by the Cochrane Collaborative on
phlebotonic agents,5 it was concluded that there is some
evidence of a reduction in limb edema with phlebotonic
agents, but overall there is not sufficient evidence to rec-
ommend their use with the exception of HCSE.
